Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

被引：0
|
作者：
Yang, Yunpeng
Zhao, Yuanyuan
Fang, Wenfeng
Huang, Yan
Zhang, Yaxiong
Ba, Yi
Wang, Zhen
Deng, Chao
Hu, Desheng
Wang, Wei
Li, Guiling
Luo, Suxia
Fu, Zhichao
Zhu, Haisheng
Wang, Huili
Zhao, Shiwei
Li, Tao
Cai, Charles
Zhang, Li
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT227
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.
    Zhou, Fei
    Li, Wei
    Chen, Yu
    Lin, Jing
    Chen, Ling
    Zhang, Huishan
    Dong, Xiaorong
    Tong, Fan
    Zhang, Ruiguang
    Yin, Yongmei
    Liang, Yan
    Yang, Nong
    Hu, Sheng
    Zhuang, Wei
    Li, Tao
    Cai, Shengli
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
    Zhou, Cai
    He, Yayi
    Ren, Shengxiang
    Li, Wei
    Zhu, Jun
    Yu, Jia
    Wang, Lei
    Xiong, Anwen
    Xu, Nong
    Mao, Chenyu
    Pan, Beiqing
    Liu, Ying
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors.
    Shi, Yuankai
    Luo, Suxia
    Zhou, Huan
    Zhou, Shengyu
    An, Shan
    Wang, Zishu
    Yang, Sheng
    Li, Ning
    Li, Xiaoli
    Yang, Xinyi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] A PHASE 1B/2, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF AN ANTI-CTLA-4 NEOBODYTM ADG116 IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1 ANTIBODY) IN PATIENTS WITH ADVANCED/ METASTATIC SOLID TUMORS: A PRELIMINARY UPDATE
    Tolcher, Anthony
    Powderly, John
    Shi, Kristine
    Zheng, Songmao
    Liu, Guizhong
    Shang, Jin
    Wang, Xinwei
    Li, Wenda
    Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A804 - A804
  • [25] Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and < for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and < for clinical potential in solid tumors such as HNSCC
    Zhu, Hengrui
    Zhang, Jinhui
    Yan, Han
    Ding, Xiao
    Yang, Juan
    Jiang, Yu
    Deng, Minjuan
    Song, Haoxuan
    Ping, Fangfang
    Sun, Fuyun
    Li, Xiaoyu
    Zhang, Lijie
    Jiang, Bin
    Song, Weiwei
    Shen, Zhirong
    Jin, Wei
    Zhang, Jiyuan
    Zhang, Yun
    CANCER RESEARCH, 2024, 84 (06)
  • [26] IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study
    Xu, Nong
    Mao, Chenyu
    Qian, Jiong
    Zheng, Yulong
    Jiang, Haiping
    Gao, Yuan
    Xiao, Cheng
    Xiong, Anwen
    Li, Wei
    He, Yayi
    Ren, Shengxiang
    Wang, Lei
    Yu, Jia
    Zhu, Jun
    Liu, Ying
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study
    Deng, Ting
    Liu, Zhigang
    Han, Zhengquan
    Zhou, Huan
    Liu, Rui
    Li, Yijing
    Li, Shaorong
    Xiu, Peng
    Wang, Shuni
    Zhang, Yiping
    Ba, Yi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [28] Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
    Markman, B.
    Coward, J.
    Nagrial, A.
    Abed, A.
    Millward, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S632 - S632
  • [29] Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors
    Strickler, John H.
    LoRusso, Patricia
    Yen, Chia-Jui
    Lin, Chia-Chi
    Kang, Yoon-Koo
    Kaminker, Patrick
    Ansell, Peter
    Bhathena, Anahlta
    Wong, Shekman
    Dudley, Matthew W.
    Naumovski, Louie
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study.
    Sheng, Xinan
    Chen, Haige
    Yao, Xin
    Hu, Yi
    Yao, Xudong
    Liu, Ziling
    Zhou, Fangjian
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345